



RON DESANTIS
GOVERNOR

SHEVAUN L. HARRIS
ACTING SECRETARY

November 23, 2020

David A. Ricks
Chief Executive Officer
Eli Lilly and Company
893 S. Delaware Street
Indianapolis, IN 46225

Dear Mr. Ricks:

It has come to my attention that some pharmaceutical manufacturers are restricting access to 340B drug pricing to health care providers participating in the 340B drug discount program, including limiting distribution of most products to 340B contract pharmacies. This is a troubling development for Florida's health care safety net providers, many of whom are significantly involved in the response to the ongoing pandemic. These safety net providers rely on funding from the 340B program to support health care services and to fund patient assistance programs that make prescription drugs more affordable for the most vulnerable Florida residents. Thus, these recent actions threaten to negatively impact the health of Florida residents.

I understand that the rationale for these changes is to ensure integrity of the program, and, as a steward of public funds, I take that concern seriously. Program integrity issues, however, are best tackled directly and specifically, rather than through broad brush approaches, and any program integrity action needs to be carefully assessed to ensure it does not inappropriately restrict access to care.

I request that you suspend these actions and instead work directly with the health care providers participating in the 340B program to address your program concerns.

Sincerely,

Beth Kidder
Deputy Secretary for Medicaid

cc: Katie Tarbet, Senior Market Manager (via email)

